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Abstract
Inflammatory (classical) monocytes residing in the bone marrow must enter the blood-
stream in order to combat microbe infection. These monocytes express high levels of
CCR2, a chemokine receptor whose activation is required for them to exit the bone marrow.
How CCR2 is locally activated in the bone marrow and how their activation promotes mono-
cyte egress is not understood. Here, we have used double transgenic lines that can visual-
ize CCR2 activation in vivo and show that its chemokine ligand CCL2 is acutely released by
stromal cells in the bone marrow, which make direct contact with CCR2-expressing mono-
cytes. These monocytes also express CXCR4, whose activation immobilizes cells in the
bone marrow, and are in contact with stromal cells expressing CXCL12, the CXCR4 ligand.
During the inflammatory response, CCL2 is released and activates the CCR2 on neighbor-
ing monocytes. We demonstrate that acutely isolated bone marrow cells co-express CCR2
and CXCR4, and CCR2 activation desensitizes CXCR4. Inhibiting CXCR4 by a specific re-
ceptor antagonist in mice causes CCR2-expressing cells to exit the bone marrow in ab-
sence of inflammatory insults. Taken together, these results suggest a novel mechanism
whereby the local activation of CCR2 on monocytes in the bone marrow attenuates an an-
choring signalling provided by CXCR4 expressed by the same cell and mobilizes the bone
marrow monocyte to the blood stream. Our results also provide a generalizable model that
cross-desensitization of chemokine receptors fine-tunes cell mobility by integrating multiple
chemokine signals.
Introduction
Innate immunity provides rapid protection from potentially harmful infection, before more
specialized acquired immunity develops against specific antigens. Molecules such as Toll-like
receptors (TLRs), which are expressed by numerous cells and respond to a variety of potential
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threats initiate innate inflammatory responses by increasing secretion of inflammatory cyto-
kines. Inflammatory cytokines then activate a cascade of cellular responses that ultimately re-
sult in recruitment of activated leukocytes to the site of infection.
One major class of inflammatory cytokines, the chemokines, are a class of small-secreted
proteins, which play diverse roles in orchestrating leukocyte trafficking by activating chemo-
kine receptors [1]. Some chemokines show developmentally controlled or constitutive expres-
sion profiles, whereas others are upregulated under pathological conditions [2]. The inducible
chemokines, such as CCL2 (a.k.a. MCP-1), are responsible for coordinated leukocyte move-
ments in response to microbial infection [3]. Peripheral monocytes circulating in the blood-
stream are a heterogeneous population of leukocytes. They can be categorized into two groups:
CCR2+ and CX3CR1+ [4]. CCR2+ monocytes, which also expressing a high level of the Ly6C
surface antigen, are enriched in the bone marrow under normal circumstances, and targeted
into inflamed tissues. For this reason, they are also called Ly6C (high) or the classical mono-
cytes. In contrast, CX3CR1+ monocytes are recruited to non-inflamed tissues, and resemble
resident macrophages.
CCL2 is not normally expressed at high levels, but its expression rapidly increases during in-
flammation [5]. CCL2 is rapidly released in the bone marrow [6, 7] and promotes emigration
of the classical monocytes [8]. CCL2 can also guide the classical monocytes in the peripheral
blood stream to the inflamed tissue, under some pathological conditions such as thioglycollate-
induced peritonitis [9] and experimental autoimmune encephalomyelitis (EAE), an animal
model of multiple sclerosis [7, 10]. During bacterial infection the activation of CCR2 on classi-
cal monocytes is required for them to exit the bone marrow, whereas it is dispensable for di-
rected movements in the bloodstream toward the infected tissue [8]. CCR2 and CCL2
knockout mice therefore cannot mobilize classical monocytes upon bacterial infection and die
because they cannot suppress bacterial growth [8]. How CCL2 acts as a mobilizing signal rather
than a long-range chemoattractant cue is not understood.
CXCL12 (a.k.a. SDF-1), acting on its receptor CXCR4, anchors hematopoietic stem cells
[11], B lineage cells and granulocytic precursors [12], and neutrophils [13] in the bone marrow.
All chemokine receptors belong to the G protein-coupled receptor (GPCR) family. Activation
of one GPCR can alter signalling of another GPCR in several different ways. For example,
CCR2 cross-desensitizes μ-opioid receptors in peripheral sensory neurons and induces height-
ened sense of pain [14]. Therefore, we reasoned that CCR2 activated during the inflammatory
response might attenuate the force that normally retains the monocytes in the bone marrow,
which is provided by CXCR4-mediated signaling.
Results
1. Stored CCL2 is released from stromal cells during inflammation
We previously established bacterial artificial chromosome (BAC)-transgenic mouse lines to
label chemokines and chemokine receptors with fluorescent proteins at the protein level, and
visualized CCR2 activation in vivo using the endocytosis of CCL2-CCR2 complexes as a read-
out, [7, 15]. Using CCL2::CCL2-mRFP;CCR2::CCR2-EGFP double transgenic mice, we exam-
ined where CCL2 and CCR2 proteins are expressed in the bone marrow under normal
conditions (Fig 1A and inset). As expected, we observed that CCR2 is expressed at the surface
of numerous monocytes in the bone marrow indicating that these receptors are not activated
(Fig 1B, green arrow). Unexpectedly, we observed that CCL2, whose expression is known to be
upregulated under pathological conditions, is also highly expressed by stromal cells under nor-
mal conditions (Fig 1B, red arrow). Intriguingly, the CCL2-positive stromal cells had elongated
morphology and were almost always in direct contact with CCR2-positive monocytes (Fig 1B,
CCR2-CXCR4 Cross-Desensitization in Monocyte Egress
PLOS ONE | DOI:10.1371/journal.pone.0128387 June 1, 2015 2 / 13
analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
green and red arrows), reminiscent of immunological synapse described for T cells and B cells
in lymph nodes [16]. These results indicate that CCL2 proteins are stored in these stromal cells
that are juxtaposed to CCR2-expressing monocytes, but are not released (because CCR2 was
not internalized but remained on the cell surface of the monocyte).
Fig 1. CCL2 acts on CXCR4-positive cells during inflammation in the bonemarrow. (Inset) Transgenic
reporter mice used in this study. 1) CCL2::CCL2-mRFP (CCL2 protein level reporter), 2) CCL2::mRFP (CCL2
transcriptional reporter), and 3) CCR2::CCR2-EGFP (CCR2 protein level reporter) (A-G) Bone marrow of
CCL2::CCL2-mRFP; CCR2::CCR2-EGFP double transgenic mice. A differential interference contrast (A) and
an overlaid fluorescent image (B) show CCL2-mRFP and CCR2-EGFP cells in close contact (arrows). (C-G)
Under normal conditions, CCR2-EGFPmostly localizes to cell surface (green arrow). After LPS injection,
most CCR2-EGFP cells are activated by CCL2, which is evident in granular CCR2-EGFP signals and
endocytic vesicles containing both CCL2-mRFP and CCR2-EGFP (yellow arrow). (H-I) Bone marrow of
CCL2::mRFP; CCR2::CCR2-EGFP double transgenic mice. After LPS injection, most CCR2-EGFP cells are
activated by endogenous CCL2, which is evident in granular CCR2-EGFP (white arrow). Scale bars, 10 μm.
doi:10.1371/journal.pone.0128387.g001
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We induced an acute inflammatory response in these mice an intraperitoneal injection of li-
popolysaccharide (LPS). We observed a striking change in CCL2 and CCR2 subcellular locali-
zation before and after an LPS injection. First, CCL2 proteins in elongated stromal cells
became less distinct (Fig 1C and 1D, red arrow), possibly because many CCL2 had been secret-
ed and less remained in these cells. We quantitated the RFP content per cell by quantitative
fluorescence imaging, and found that LPS injection significantly decreased CCL2-mRFP per
cell indicating its release (Fig 1E and 1F; S1A Fig). Because CCL2 is known to be upregulated
by inflammatory insults [1], we asked whether LPS increases the number of CCL2-expressing
cells in the bone marrow. For this, we used a different transgenic reporter CCL2::mRFP (CCL2
transcriptional reporter), in which CCL2-positive cells express mRFP only but not
CCL2-mRFP fusion proteins (Fig 1 inset). For this reason, the pattern of mRFP signal in the
CCL2-expressing cells is not affected by LPS, which allows consistent cell counting (S1B Fig).
LPS injection led to an approximately 20% increase in the number of CCL2-mRFP expressing
cells (S2A Fig; Fig 1H and 1I). Therefore, although many cells in the bone marrow express
CCL2 under normal conditions, more cells begin to express it during inflammation. Second,
most CCR2 appeared punctate, which localized both to the cell surface and cytosol of the
monocytes (Fig 1D, yellow arrow). Overall, the number of CCR2-positive cells became smaller
after the LPS injection, possibly because many of them left the bone marrow (Fig 1E–1G; S2B
Fig). Importantly, the monocytes that were still in the bone marrow contained both CCL2 and
CCR2 proteins (Fig 1D and 1F, yellow arrow). Because no cells contained both CCR2 and
CCL2 under normal conditions (Fig 1C), we concluded that the CCL2 and CCR2 double posi-
tive puncta indicate ligand-receptor complexes that are endocytosed after CCR2 activation.
CCR2 activation could be seen even when CCL2 is not fluorescently tagged, which was evident
in punctate CCR2-EGFP (Fig 1H–1J; Fig 2D–2F). Taken together, these results indicate that
CCL2 stored in the bone marrow under normal conditions is rapidly released during inflam-
mation and activates CCR2 expressed by neighboring monocytes.
2. CCR2 activated monocytes express CXCR4
Next, we sought to ask whether CCR2-positive monocytes co-express CXCR4 and whether
CCL2-CCR2 signaling is activated in this population of cells during inflammation. We used an-
other reporter mouse line, CXCR4::EGFP, in which the transcription factors that normally reg-
ulate the expression of cxcr4 gene additionally drive the expression of EGFP [17]. This mouse
represents a transcriptional reporter, and unlike the protein level reporter CCR2-EGFP,
CXCR4-expressing cells contain EGFP in the cytosol regardless of the status of CXCR4 activa-
tion (Fig 2 inset). CXCR4-positive cells include many cell types, including hematopoietic stem
cells and monocytes. We challenged CCL2::CCL2-mRFP; CXCR4::GFP double transgenic mice
with LPS and visualized whether CCL2 released from the stromal cell during inflammation
acts on CXCR4-expressing cells (Fig 2A–2C). Indeed, clear CCL2-mRFP signal was visible in-
side some of CXCR4-positive cells only when the animal was injected with LPS (Fig 2B, yellow
arrow; Fig 2B, red arrow), indicating that these cells co-express CCR2 and are likely to be
CCR2/CXCR4 double positive monocytes. In contrast to CCL2::CCL2-mRFP; CCR2::
CCR2-EGFP mice, in which most CCR2-positive cells contained intracellular CCL2-mRFP
after LPS injection (Fig 1D and 1F), a smaller portion of CXCR4-positive cells showed internal-
ized CCL2-mRFP, and these cells were in close proximity to CCL2-positive stromal cells (Fig
2B). To understand how the cells that co-express CCR2 and CXCR4 interact with CXCL12, the
ligand for CXCR4, we crossed another transgenic mouse line, CXCL12::CXCL12-mRFP [7, 15]
with CCR2::CCR2-EGFP (Fig 2D–2F). CCR2-positive cells (green arrow) were also juxtaposed
with CXCL12-expressing cells (red arrow), which had elongated morphology similar to
CCR2-CXCR4 Cross-Desensitization in Monocyte Egress
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Fig 2. CCR2-positive cells are neighbored by CXCL12-positive cells in the bonemarrow. (inset)
Transgenic reporter mice used in this study. (A-C) Bone marrow of CCL2::CCL2-mRFP; CXCR4::EGFP
double transgenic mice. Note that CXCR4::EGFP is a transcriptional reporter, and therefore EGFP localizes
to the entire cell in which CXCR4 is expressed (C). Most CCL2-mRFP cells are in close proximity to CXCR4::
EGFP cells (green arrow) under normal conditions. After LPS injection, these CXCR4::EGFP cells now
contain CCL2-mRFP granules (yellow arrow), indicating endocytosis of CCL2-mRFP/CCR2 (unlabeled
endogenous CCR2) (B’). (D-F) Bone marrow of CXCL12::CXCL12-mRFP; CCR2::CCR2-EGFPmice.
CCR2-postive cells (green arrow) are often in contact with CXCL12-positive cells (red arrow). Upon LPS
injection, CCR2 is activated (white arrow: granular CCR2-EGFP signal) independently from CXCL12
signaling (because CXCL12-mRFP is not endocytosed by CCR2 positive cells). (G-I) Bone marrow of
CXCL12::CXCL12-mRFP; CXCR4:EGFPmice. CXCR4 activation, which could have been visualized by
CXCL12 (red arrow) endocytosis by CXCR4-positive cells (green arrow), is not increased by LPS injections.
Scale bars, 10 μm.
doi:10.1371/journal.pone.0128387.g002
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CCL2-positive cells (Figs 1B and 2E, red arrows). Upon LPS injection, CCR2 proteins become
punctate, indicating CCR2 activation (Fig 2E, white arrow). These puncta never contained any
CXCL12, indicating that CCR2-positive cells that are in close proximity to CXCL12-expressing
cells were activated by endogenous CCL2 that are not labelled in this mouse line (Fig 2J). LPS
injection did not induce activation of CXCR4 (i.e. internalization of CXCL12 by CXCR4-posi-
tive cells) (Fig 2G–2I). Consistent with this result, CXCL12-mRFP intensity was not changed
by LPS injection indicating that its release is not affected by inflammation (S1C Fig). These re-
sults confirm that CCL2 released from the stromal cells act locally and activates CCR2 on near-
by cells, which co-express CXCR4.
Next, we examined whether these cells in the bone marrow co-express functional CCR2 and
CXCR4 by performing Fura 2-based calcium imaging experiments on acutely isolated bone
marrow cells. Activation of CCR2 and CXCR4 in most cells results in a transient rise in intra-
cellular Ca2+ in a pertussis toxin-sensitive manner, which can be measured by calcium imaging
[18, 19]. We treated acutely isolated bone marrow cells sequentially with vehicle solution,
CCL2 and CXCL12 (Fig 3A), and categorized them according to their responses (Fig 3B). Most
CCR2-positive cells (which responded to CCL2) also responded to CXCL12, indicating that
the majority of CCR2-positive cells in the bone marrow indeed co-express functional CXCR4
(Fig 3C).
3. Activation of CCR2 desensitizes CXCR4 signaling which normally
retains monocytes
Because CXCL12/CXCR4 signaling is a well known signal that anchors various cells in the
bone marrow [11], we hypothesized that the activation of CCR2 may desensitize CXCR4 ex-
pressed by the same cells, resulting in their mobilization. First, we again used Fura 2-based cal-
cium imaging to investigate whether CCR2 activation desensitizes CXCR4 signaling. Acutely
isolated bone marrow cells were sequentially treated with CCL2 and CXCL12 as previously,
but this time higher doses of CCL2 (20 or 40 nM) were used (Fig 4A). Indeed, cells that were
pre-treated with CCL2 showed a dose-dependent reduction in their responsiveness to
CXCL12, indicating the desensitization of CXCR4 in these cells (Fig 4B). Reduction of CXCR4
Fig 3. CCR2 and CXCR4 are co-expressed by bonemarrow cells. (A) Acutely isolated bone marrow cells were plated on a cover slip and their responses
to CCL2 (10 nM) and CXCL12 (10 nM) were measured by Fura 2-based calcium imaging. The response to ATP, which increases intracellular [Ca2+] by
purinergic receptors, indicates that the recorded cell was alive. (B) Venn diagram showing percentage of CCL2- and/or CXCL12-responsive cells. (C) More
than 80% of CCL2-responsive cells also responded to CXCL12.
doi:10.1371/journal.pone.0128387.g003
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activity was likely to result from CXCR4 desensitization rather than inactivation, because these
cells were able to respond to higher doses of CXCL12 (S3 Fig). This result supports our hypoth-
esis and predicts that antagonizing CXCR4-mediated signaling would promote the emigration
of CCR2-positive monocytes even in the absence of any inflammatory stimuli. We tested this
possibility by injecting CCR2-EGFP mice with AMD3100, a CXCR4 antagonist, and measuring
the percentage of CCR2-positive cells in the bone marrow and in the peripheral blood by flow
cytometry. In accordance with our prediction, an acute intraperitoneal injection of AMD3100
resulted in a significant decrease in the number of CCR2-positive cells in the bone marrow (Fig
5A). In contrast, the number of circulating CCR2-positive monocytes in the circulating blood
increased (Fig 5B), suggesting that antagonizing CXCR4 activity indeed is sufficient to mobilize
CCR2-positive monocytes from the bone marrow.
Discussion
Recent studies by Pamer and colleagues showed that CCL2-CCR2 signaling participates in the
“release” of classical monocytes from the bone marrow rather than in their “recruitment” to-
ward the peripheral target [8]. In CCR2 knockout mice, and to a lesser extent CCL2 knockout
mice, classical monocytes do not enter the bloodstream efficiently and instead accumulate in
the bone marrow after bacterial infection. In addition ccr2-/-monocytes transferred to the
bloodstream travel normally to the infected spleen [8]. Bacterial infection causes a rise in TLR
ligands in the circulation, which is delivered to the bone marrow through sinusoidal endotheli-
um. As a result, TLRs expressed by nearby cells, which include CXCL12-abundant reticular
(CAR) cells, are activated. And it was believed that these cells then “up-regulate” CCL2, which
causes CCR2-positive monocytes to exit the bone marrow through an unknown mechanism.
Here we showed that most CCR2-positive cells (~80%) in the bone marrow co-express
CXCR4 (Fig 3C). Co-expression CCR2 and CXCR4 is consistent with the fact that CAR cells,
which constitutively secrete CXCL12 under normal conditions, is one of the major sources of
CCL2 during inflammation [6]. However, our results indicate that these and other bone mar-
row resident stromal cells express a significant level of CCL2, which is not released but stored
Fig 4. CCR2 desensitizes CXCR4. (A) Calcium imaging on acutely isolated bone marrow cells. A low (10 nM) or high (40 nM) of CCL2 was treated for 5 min
before a CXCL12 application. ATP-responsiveness at the end of experiment shows cell viability. As shown in Fig 3, most CCL2-responsive cells also
responded to CXCL12 (yellow). When a higher dose of CCL2 was pre-treated, however, most cells did not respond to CXCL12 (red). (B) Quantification of
calcium imaging. n = 50, 95, and 30, respectively; *p<0.05 vs. 10 nM, ***p<0.001 vs. 10 nM or 20 nM; Fisher’s exact test.
doi:10.1371/journal.pone.0128387.g004
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in the intracellular vesicles (Fig 1B). The premade and stored CCL2 is then rapidly released
upon the activation of the inflammatory response and activates CCR2 expressed by monocytes
in close proximity (Fig 1C and 1D; S1A Fig). Although CXCL12 is also expressed in the bone
marrow stromal cells under normal conditions, its cellular localization is not changed by in-
flammation (Fig 2D–2I; S1C Fig) suggesting that CXCL12 may be constitutively secreted in
contrast to CCL2 whose release is regulated by inflammation. This result is consistent with our
previous finding that the release of CCL2 is regulated by the calcium-dependent regulated
pathway in peripheral sensory neurons, whereas CXCL12 is constitutively released [20].
It was unclear how CCL2, which is known to have a chemoattractant activity, promotes the
migration of CCR2-positive monocytes away from the source of CCL2 gradient in the bone
marrow. We showed that CCR2 and CXCR4 are co-expressed by the majority of bone marrow
monocytes (Fig 3). We also showed that activation of CCR2 cross-desensitizes CXCR4 (Fig 4).
Because CXCL12-CXCR4 signaling anchors and immobilizes the cell in the bone marrow, we
hypothesize that CCL2-CCR2 signaling decreases this immobilization and increases overall
mobility of the cells resulting in their migration out of the bone marrow (Fig 6). In accordance
with our hypothesis, the classical monocytes identified by an independent way (CD11b
+ Ly6Chigh) was also mobilized by AMD3100 (S4A Fig). Interestingly, AMD3100 did not mo-
bilize the nonclassical monocyte subset (CD11b+ Ly6Clow) (S4C Fig) in contrast CCR2-posi-
tive classical monocytes (S4B Fig), suggesting that these cells might be retained by additional
signals. Indeed, the nonclassical monocyte subset expresses a high level of CX3CR1, which was
recently shown to retain cells in the bone marrow [21]. Therefore, CX3CR1 may provide an ad-
ditional anchoring signal to the nonclassical but not classical monocytes.
Monocytes express not only CCR2 but also other chemokine receptors such as CCR5 [22],
and CCR2 can be activated not only by CCL2 but also by CCL7 [1]. Other chemokines that act
on CCR2 and other chemokine receptors may also regulate CXCR4 signaling on monocytes
and their egress. CXCL12, which provides an anchoring signal to CXCR4-positive monocytes,
Fig 5. CCR2-positive cells can be mobilized by CXCR4 inhibition.CCR2::CCR2-EGFPmice were injected with AMD3100 or saline, and the percentage
of EGFP-positive cells in the bone marrow or in the blood was measured by flow cytometry. AMD3100 injections decreased CCR2-EGFP cells in the bone
marrow (A), and increased them in the bloodstream (B). n = 4 each; **p<0.01; Mann-Whitney test.
doi:10.1371/journal.pone.0128387.g005
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not only binds to CXCR4 but also to CXCR7 [1]. CXCR7 can function as a scavenger for
CXCL12 to regulate the availability of CXCL12 to CXCR4. Although leukocytes generally do
not express CXCR7 [23], bone marrow-resident mesenchymal stem cells do [24]. Therefore, it
is also possible that CXCR7 may regulate monocyte egress by regulating the concentration of
CXCL12 in the bone marrow.
One potential mechanism for CCR2-mediated CXCR4 desensitization is direct interactions
between receptors. Indeed, GPCR family members exhibit extensive homo- and hetero-oligo-
merization, and it has been shown that CCR2 and CXCR4 form heterodimers [25, 26]. Be-
cause CCL2 binding induces extensive endocytosis of cell surface CCR2 both in vitro [27] and
in vivo ([28] and this paper), it is likely that a surge of CCL2 release from the bone marrow-
resident stromal cells induces internalization of CCR2-CXCR4 complexes in juxtaposed
monocytes and weakens the anchoring signal provided by constitutively released CXCL12.
Another possibility is crosstalk between receptor-coupled intracellular signalling pathways. In
this case, other GPCRs may also regulate CXCR4 activity and monocyte egress. In this regard,
it is intriguing that CXCR4 hetero-oligomerize with α-adrenergic receptor in the vascular
smooth muscle [29]. Because bone marrow progenitor cells express α-adrenergic receptors
[30], our model may be extended to partially explain sympathetic control of the innate immu-
nity [31].
Overall, our results explain how a rapid egress of bone marrow-resident monocytes is con-
trolled by chemokine receptor crosstalk in the bone marrow niche where stromal cells and
leukocytes form intricate networks, and suggest the antagonism of CXCR4 signaling as a prom-
ising therapeutic approach to treat monocytopenia. Indeed, WHIM (warts, hypogammaglobu-
linemia, infections, and myelokathexis) syndrome, an autosomal dominant disorder often
accompanied by monocytopenia, is caused by a single amino acid mutation in CXCR4, which
Fig 6. Proposedmodel: monocyte egress by CCR2-mediated cross-desensitization of CXCR4.Monocytes in the bone marrow co-express CXCR4 and
CCR2. These cells are juxtaposed to bone marrow-resident cells, which express their respective ligands, CXCL12 and CCL2. (A) Under normal conditions,
monocytes are retained by CXCR4 signaling, which is activated by constitutively secreted CXCL12. CCR2 on these monocytes is not active as its ligand
CCL2 is stored but not released. (B) During inflammation, stored CCL2 is rapidly released and activates CCR2, which desensitizes CXCR4 and promotes
cell migration.
doi:10.1371/journal.pone.0128387.g006
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PLOS ONE | DOI:10.1371/journal.pone.0128387 June 1, 2015 9 / 13
blocks its endocytosis and therefore increases CXCR4 activity [32]}. Therefore, inhibiting
CXCR4 signaling could also be therapeutic for other diseases characterized by immobile
monocytes.
Materials and Methods
Animal
All animal experiments were approved by the Institutional Animal Care and Use Committee at
Yonsei University College of Medicine and Northwestern University. Animals were housed
with food and water ad libitum and kept on 12-hours light cycle.
The following reporter transgenes were used: (1) CCR2::CCR2–EGFP (protein level re-
porter), (2) CCL2:CCL2–mRFP (protein level reporter), (3) CCL2::mRFP (transcriptional
reporter), (4) CXCL12::CXCL12-mRFP [7], and (5) CXCR4::EGFP (transcriptional report-
er) (GENSAT project, Rockefeller University, New York, NY). Mice were injected intraperi-
toneally with 10 mg/kg lipopolysaccharide (LPS) diluted in saline and were killed after
6 hours.
Histology and imaging
For tissue sections, lumbar vertebrate columns were immediately removed from mice transcar-
dially perfused with 4% paraformaldehyde and post-fixed for 4 h. The tissues were sectioned at
14 μm and stored at -20°C until use. Images were taken in a laser-scanning confocal micro-
scope (Olympus, Melville, NY, USA) equipped with a 60x oil immersion objective lens (numer-
ical aperture, 1.40). For quantitative analysis, the tissue samples to be compared were prepared
together in identical conditions. Then the images were taken with identical acquisition settings.
All images used for quantitative analysis covered 200μm x 200μm x 10μm per field, which was
taken by 1 μm-thick optical section in 1 μm interval. For cell counting, we used ImageJ plugin
Cell Counter. We went through individual optical sections for accurate measurement of cell
numbers per field. For RFP intensity measurement, we first made a Z-projection using ImageJ
and then made ROIs by manually drawing cell boundaries. We only analyzed non-overlapping
cells. For 3D reconstruction, we used ImageJ plugin 3D Viewer.
Bone marrow cell isolation and flow cytometry
CCR2::CCR2-EGFP mice were injected intraperitoneally with either AMD3100 (10mg/kg) or
saline at 8 am. Two hours later mice were anesthetized, both blood and bone marrow were har-
vested using standard methods. Single cell preparations were then counted and re-suspended
in FACS buffer (PBS with 0.1% BSA) to 1x106 cells/ml. The following antibodies were used for
multiple fluorescence labeling, all from Becton Dickinson: CD11b-APC and Ly6C-PE.
CCR2-EGFP occupied the GFP channel, and propidium iodide was added to each sample. Sin-
gle channels were used for compensation adjustment then multi-color fluorescence was ac-
quired on a Becton Dickinson flow cytometer. Initially CCR2-EGFP+ cells were identified
from the population of viable cells. To examine Ly6C+/CCR2+ monocytes, the gating strategy
employed involved selecting CD11b+ cells followed by examining the Ly6C/CCR2 co-labeled
population.
Calcium imaging
The AM form of fura-2 (Invitrogen) was used as the fluorescent Ca2+ indicator. All measure-
ments were made at room temperature (21°C) as described previously (Bhangoo et al. 2007).
Acutely isolated bone marrow cells loaded with fura-2AM (3 μM) were mounted onto the
CCR2-CXCR4 Cross-Desensitization in Monocyte Egress
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chamber (500 μL total volume), which was then placed onto the inverted microscope, and per-
fused continuously by balanced salt solution (in mM: 145 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10
N-2-hydroxyethylpiperazine-N0-2-ethanesulfonic acid, and 10 glucose). Ratiometric images
were collected every 3 s and Ca2+ concentration was calculated by a standard curve generated
using calcium calibration buffer kit (C-3721, Invitrogen) using MetaFluor software (Molecular
Devices). For CCL2 and CXCL12 (R & D Systems, Minneapolis, MN, USA), we applied 1 mL
of solution directly to the bath chamber after stopping the flow.
Statistics
Data were presented as mean ± SEM. Mann-Whitney test or Fisher’s exact test were performed
as described in the figure legend. Statistical significance was set at p< 0.05.
Supporting Information
S1 Fig. LPS induces the release of stored CCL2 in the bone marrow. (A) Normalized net
RFP intensity per cell was measured in CCL2::CCL2-mRFP mouse (CCL2 protein level report-
er) injected with LPS or vehicle. LPS injection significantly decreased RFP intensity per cell
(which correlates with CCL2 contents), indicating CCL2 release. (B) RFP intensity did not
change in CCL2::mRFP (transcriptional reporter). (C) CXCL12-mRFP release was not affected
by LPS. The numbers indicate the numbers of analyzed cells taken from three independently
performed experiments.
(EPS)
S2 Fig. The numbers of CCL2- and CCR2-positive cells in the bone marrow. (A-B) CCL2-
and CCR2-positive cells were counted in optical sections with the dimension of 200μm x
200μm x 10μm. LPS injection increased in CCL2-positive cells and decreased CCR2-positive
cells in the bone marrow. (A) CCL2::mRFP. (B) CCR2::CCR2-EGFP. n = 4; p<0.05; Mann-
Whitney test.
(EPS)
S3 Fig. CCR2 desensitizes CXCR4.Quantification of calcium imaging on acutely isolated
bone marrow cells. Cells were treated with CCL2 for 5 min and then with CXCL12 with indi-
cated concentrations. n = 22, 10, 63, 30, respectively; p<0.001 vs. 20 nM CCL2 / 20 nM
CXCL12 group; Fisher’s exact test.
(EPS)
S4 Fig. AMD3100 mobilizes the classical monocytes. (A-C) Quantification of the classical
(CD11b+Ly6Chigh) and nonclassical (CD11b+Ly6Clow) monocyte subsets by flow cytometry.
CCR2::CCR2-EGFP mice were injected with AMD3100 or saline, and the percentage of EGFP-
positive cells in the bone marrow or in the blood was measured by flow cytometry. AMD3100
decreased the classical monocytes in the bone marrow and increased them in the bloodstream
(A, B). AMD3100 did not change distribution of the nonclassical monocytes (C). n = 3;
p<0.01; Mann-Whitney test.
(EPS)
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